CSTLCastle Biosciences, Inc.
Price
+47%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, growth steady, the market undecided.
Charts
As reported to the SEC, without any scoring.
Castle Biosciences, Inc. (CSTL) reported revenue of $104M in Q2 2026 (quarter ended Jun 30, 2026), up 20% from the same quarter a year earlier. That came with a gross margin of 77% and net loss of $2.1M. For the full year FY2025, revenue was $344M (+3.7% year on year) and net income −$24M. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 30, 2026Castle Biosciences Reports Second Quarter 2026 Results.Earnings release · press release
- May 6, 2026Castle Biosciences Reports First Quarter 2026 Results.Earnings release · press release
- Feb 26, 2026Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #11 of 21 by RyuScore